A Phase 2/3 interventional study of palivizumab in Respiratory Syncytial Virus Infection, Premature Birth and Bronchopulmonary Dysplasia, sponsored by Abbott. Completed at 19 sites in Russian Federation. Open to participants aged Up to 2 Years. Per ClinicalTrials.gov, last updated 2011-07-19.
Sponsored by Abbott · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
100 Russian children of 2 years of age and less in high-risk populations (preterm, and/or with heart and lung problems) will receive palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe respiratory syncytial virus (RSV) infection in order to study the safety and efficacy of the drug in Russian subjects.
A prospective, multicenter, open-label, non-comparative study of safety and efficacy of palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe lower respiratory tract respiratory syncytial virus infection in 100 Russian children of 2 years of age and less in high-risk populations (preterm infants [less than or equal to 35 weeks gestational age], infants with bronchopulmonary dysplasia [BPD], and infants with hemodynamically significant congenital heart disease [HSCHD]).
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
This study's enrollment of 100 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Browse Respiratory Syncytial Virus Infections studies →Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet all of the following criteria to be enrolled into the study:
Infants at high risk of severe RSV infection defined as fulfilling at least one of the following:
Exclusion Criteria:
Subjects meeting any of the following criteria are not eligible for the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
palivizumab 15 mg/kg intramuscularly every 30 days for 3 to 5 injections
Biological: palivizumab
palivizumab 15 mg/kg intramuscularly
Also known as: ABT-315 (MEDI-493), Synagis 15 mg/kg intramuscularly
Frequency of Adverse Events
Treatment-emergent adverse events were defined as those occurring after study drug initiation and within 30 and 100 days after the last dose of study drug. The number of subjects experiencing a serious or nonserious treatment-emergent adverse event within 30 days after the last dose of study drug is summarized. See the Reported Adverse Events section for details.
Time frame: Through 30 days following the last injection of palivizumab
Number of Hospitalizations Due to Respiratory Syncytial Virus (RSV)
Number of subjects experiencing an RSV hospitalization
Time frame: Through 30 days following the last injection of palivizumab
Total Number of RSV Hospitalization Days
All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.
Time frame: Through 30 days following the last injection of palivizumab
Total RSV Hospitalization Days With Increased Supplemental Oxygen Requirement
All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.
Time frame: Through 30 days following the last injection of palivizumab
Number of Intensive Care Unit (ICU) Admissions During RSV Hospitalization
Outcome measure refers to the number of subjects admitted to the ICU during RSV hospitalization. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.
Time frame: Through 30 days following the last injection of palivizumab
Total Days of RSV ICU Stay
All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.
Time frame: Through 30 days following the last injection of palivizumab
Number of Subjects Who Received Mechanical Ventilation During RSV Hospitalization
All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.
Time frame: Through 30 days following the last injection of palivizumab
Total Days of Mechanical Ventilation During RSV Hospitalization
All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.
Time frame: Through 30 days following the last injection of palivizumab
Subjects were enrolled into the study in 3 geographic areas of the Russian Federation. Recruitment began in November 2009 and ended in December 2009. Subjects at high risk of severe RSV infection (including preterm infants, infants with BPD, and infants with HSCHD) were identified as candidates for the study on the basis of routine assessments.
| Milestone | Palivizumab |
|---|---|
| Started | 100 |
| Completed | 94 |
| Not completed | 6 |
| Withdrew: Adverse event | 1 |
| Withdrew: Parent refused to continue participation | 1 |
| Withdrew: Parent unable to perform site visit | 4 |
Treatment-emergent adverse events were defined as those occurring after study drug initiation and within 30 and 100 days after the last dose of study drug. The number of subjects experiencing a serious or nonserious treatment-emergent adverse event within 30 days after the last dose of study drug is summarized. See the Reported Adverse Events section for details.
| participants | Palivizumab |
|---|---|
| Frequency of Adverse Events | 41 |
Number of subjects experiencing an RSV hospitalization
| participants | Palivizumab |
|---|---|
| Number of Hospitalizations Due to Respiratory Syncytial Virus (RSV) | 0 (0.0 to 3.6) |
All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.
No measurements were reported for this outcome.
All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.
No measurements were reported for this outcome.
Outcome measure refers to the number of subjects admitted to the ICU during RSV hospitalization. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.
No measurements were reported for this outcome.
All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.
No measurements were reported for this outcome.
All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.
No measurements were reported for this outcome.
All secondary outcome measures were related to hospitalization due to RSV infection. No RSV hospitalizations occurred during the study; therefore, evaluation of the secondary outcome measures was not possible.
No measurements were reported for this outcome.
Collected over From date of first dose of study drug through 100 days after the last dose of study drug. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Palivizumab | — | 10/100 (10%) | 39/100 (39%) |
| Event | Palivizumab |
|---|---|
| BronchitisInfections and infestations | 4/100 |
| EnteritisGastrointestinal disorders | 3/100 |
| Supraventricular tachycardiaCardiac disorders | 1/100 |
| PneumoniaInfections and infestations | 1/100 |
| TonsillitisInfections and infestations | 1/100 |
| Upper respiratory tract infectionInfections and infestations | 1/100 |
| Event | Palivizumab |
|---|---|
| RhinitisInfections and infestations | 19/100 |
| Upper respiratory tract infectionInfections and infestations | 8/100 |
| BronchitisInfections and infestations | 3/100 |
| Bronchopulmonary dysplasiaRespiratory, thoracic and mediastinal disorders | 3/100 |
| TeethingGastrointestinal disorders | 2/100 |
| Ear infectionInfections and infestations | 2/100 |
| NasopharyngitisInfections and infestations | 2/100 |
| Respiratory tract infectionInfections and infestations | 2/100 |
| Respiratory tract infection viralInfections and infestations | 2/100 |
| NervousnessPsychiatric disorders | 2/100 |
| Age Continuous(months) | Palivizumab |
|---|---|
| Mean | 8.2 ± 6.3 |
| Age, Customized(participants) | Palivizumab |
|---|---|
| Between 0 and 3 months | 28 |
| Between 4 and 6 months | 24 |
| Between 7 and 9 months | 14 |
| Between 10 and 12 months | 7 |
| Between 13 and 15 months | 8 |
| Between 16 and 18 months | 10 |
| Between 19 and 21 months | 5 |
| Between 22 and 24 months | 4 |
| Sex: Female, Male(Participants) | Palivizumab |
|---|---|
| Female | 52 |
| Male | 48 |
| Region of Enrollment(participants) | Palivizumab |
|---|---|
| Russian Federation | 100 |
| Gestational Age(weeks) | Palivizumab |
|---|---|
| Mean | 33.4 ± 5.1 |
| Gestational Age, categorical(participants) | Palivizumab |
|---|---|
| Less than 29 weeks gestational age | 23 |
| Between 29 and 32 weeks gestational age | 22 |
| Between 33 and 35 weeks gestational age | 22 |
| Greater than 35 weeks gestational age | 33 |
| Infants born <= 35 weeks gestational age and <= 6 months of age at enrollment(participants) | Palivizumab |
|---|---|
| Yes | 33 |
| No | 67 |
| Infants <= 24 months of age at enrollment and with a diagnosis of BPD(participants) | Palivizumab |
|---|---|
| Yes | 46 |
| No | 54 |
1 further baseline measures are reported on the registry.
The record gives a start of Nov 2009, a primary completion of Apr 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palivizumab
Respiratory Syncytial Virus Infections →